🇺🇸 FDA
Pipeline program

Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets

CTRIAL-IE 14-06

Phase 3 small_molecule active

Quick answer

Xtandi - 40 mg soft capsules, Flutamide 250 mg Tablets, Casodex® 50 mg Film-coated Tablets for Metastatic Prostate Cancer is a Phase 3 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Cancer Prevention Pharma (Ireland) Limited
Indication
Metastatic Prostate Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials